IMMU — Mendus AB (publ) Share News
0.000.00%
Last trade - 00:00- SEK346.22m
- SEK304.26m
Brief: Immunicum AB - Receives Orphan Drug Designation From EMA
Brief: Immunicum Q4 Loss For Period At SEK 47.6 Mln
Brief: Immunicum Appoints Lotta Ferm New Interim CFO
Brief: Immunicum Plans To Expand Its Research And Process Development Facilities In Leiden, The Netherlands
Brief: Immunicum: Michael Oredsson To Resign His Position As Chairman
Brief: Immunicum Gets FDA Fast Track Designation For Ilixadencel In Gastrointestinal Stromal Tumors
Brief: Immunicum To Acquire DCprime B.V.
Brief: Immunicum Q3 Operating Loss Narrows To SEK 21.7 Mln
Brief: Immunicum Updates On Strategy
Brief: Immunicum Appoints Sven Rohmann As CEO
Brief: Immunicum Q2 Operating Loss Narrows To SEK 25.2 Mln
Brief: Immunicum Updates On Survival Data From Phase II Mereca Trial Of Ilixadencel In Kidney Cancer
Brief: Immunicum: Phase I/II Clinical Trial On Ilixadencel Meets Primary Endpoint Of Safety
Brief: Immunicum Appoints Peter Hein Interim CFO
Brief: Immunicum Gets Regenerative Medicine Advanced Therapy Designation From FDA
Brief: Immunicum Q1 Net Loss Widens To SEK 31.7 Million
Brief: Immunicum CFO Michaela Gertz Resigns
Brief: Immunicum Q4 Operating Loss Widens To SEK 40.1 Million
Brief: Immunicum AB Presents Updated Data From Phase Ii Mereca Trial Of Ilixadencel In Kidney Cancer